313 related articles for article (PubMed ID: 15563422)
1. [Hodgkin's disease and Epstein-Barr virus].
Depil S; Moralès O; Auriault C
Ann Biol Clin (Paris); 2004; 62(6):639-48. PubMed ID: 15563422
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-associated Hodgkin's lymphoma.
Gandhi MK; Tellam JT; Khanna R
Br J Haematol; 2004 May; 125(3):267-81. PubMed ID: 15086409
[TBL] [Abstract][Full Text] [Related]
3. [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].
Beck Z; Illés A; Keresztes K; Bessenyei B; Szöllosi Z; Kis A; Oláh E
Orv Hetil; 2006 Aug; 147(33):1539-44. PubMed ID: 17037676
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus and Hodgkin's lymphoma.
Andersson J
Herpes; 2006 May; 13(1):12-6. PubMed ID: 16732997
[TBL] [Abstract][Full Text] [Related]
5. Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis.
Mitarnun W; Pradutkanchana J; Takao S; Saechan V; Suwiwat S; Ishida T
J Med Assoc Thai; 2002 May; 85(5):552-9. PubMed ID: 12188384
[TBL] [Abstract][Full Text] [Related]
6. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma.
Marshall NA; Culligan DJ; Tighe J; Johnston PW; Barker RN; Vickers MA
Exp Hematol; 2007 Apr; 35(4):596-604. PubMed ID: 17379070
[TBL] [Abstract][Full Text] [Related]
7. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma.
Kwon JM; Park YH; Kang JH; Kim K; Ko YH; Ryoo BY; Lee SS; Lee SI; Koo HH; Kim WS
Ann Hematol; 2006 Jul; 85(7):463-8. PubMed ID: 16534596
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cells and EBV associated malignancies.
Li J; Qian CN; Zeng YX
Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study.
Keegan TH; Glaser SL; Clarke CA; Gulley ML; Craig FE; Digiuseppe JA; Dorfman RF; Mann RB; Ambinder RF
J Clin Oncol; 2005 Oct; 23(30):7604-13. PubMed ID: 16186595
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease.
Glavina-Durdov M; Jakic-Razumovic J; Capkun V; Murray P
Br J Cancer; 2001 May; 84(9):1227-34. PubMed ID: 11336475
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin's disease and peripheral T-cell lymphoma: composite lymphoma with evidence of Epstein-Barr virus infection.
Niedobitek G; Baumann I; Brabletz T; Lisner R; Winkelmann C; Helm G; Kirchner T
J Pathol; 2000 Aug; 191(4):394-9. PubMed ID: 10918214
[TBL] [Abstract][Full Text] [Related]
14. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
15. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.
Diepstra A; van Imhoff GW; Schaapveld M; Karim-Kos H; van den Berg A; Vellenga E; Poppema S
J Clin Oncol; 2009 Aug; 27(23):3815-21. PubMed ID: 19470931
[TBL] [Abstract][Full Text] [Related]
16. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease.
Meij P; Vervoort MB; Bloemena E; Schouten TE; Schwartz C; Grufferman S; Ambinder RF; Middeldorp JM
J Med Virol; 2002 Nov; 68(3):370-7. PubMed ID: 12226824
[TBL] [Abstract][Full Text] [Related]
17. [EBV-positive Hodgkin's lymphoma in children under 10 years].
Macák J; Plank L; Habanec B; Fabián P; Curík R; Nieslanik J; Bobot L; Vácha P; Utíkal Z; Dvorácková J
Vnitr Lek; 2000 Jul; 46(7):387-90. PubMed ID: 15635798
[TBL] [Abstract][Full Text] [Related]
18. Screening for Epstein-Barr virus in Hodgkin's lymphoma.
Khan G
Methods Mol Biol; 2009; 511():311-22. PubMed ID: 19347303
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma.
Chang ET; Zheng T; Lennette ET; Weir EG; Borowitz M; Mann RB; Spiegelman D; Mueller NE
J Infect Dis; 2004 Jun; 189(12):2271-81. PubMed ID: 15181575
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus in Hodgkin's disease: more than just an innocent bystander.
Oudejans JJ; Jiwa NM; Meijer CJ
J Pathol; 1997 Apr; 181(4):353-6. PubMed ID: 9196428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
